Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$39.2B
282M shares
52-week range
$108.35 – $160.27
58% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
www.agilent.comNo one on the platform currently holds A.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 300,300 | $34.2M |
| Bridgewater Associatesas of 2026-03-31 | 73,689 | $8.4M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-30 | $0.2550 | 2026-07-22 |
| 2026-03-31 | $0.2550 | 2026-04-22 |
| 2026-01-06 | $0.2550 | 2026-01-28 |
| 2025-09-30 | $0.2480 | 2025-10-22 |
| 2025-07-01 | $0.2480 | 2025-07-23 |
| 2025-04-01 | $0.2480 | 2025-04-23 |
| 2024-12-31 | $0.2480 | 2025-01-22 |
| 2024-10-01 | $0.2360 | 2024-10-23 |
| 2024-07-02 | $0.2360 | 2024-07-24 |
| 2024-04-01 | $0.2360 | 2024-04-24 |
No one on the platform has traded A yet.
| 2023-12-29 | $0.2360 | 2024-01-24 |
| 2023-10-02 | $0.2250 | 2023-10-25 |
| Execution date | Ratio |
|---|---|
| 2014-11-03 | 1398-for-1000 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SLS Look at this SHORT IDIOT TOOL - Stuck its MEAT into the GRINDER... Dr. Tsirigotis KNOWS --- He absolutely Knows -- treats more REGAL P3 Patients than any other clinician and Stated on the Record - "MOS for patients on BAT is extremely poor, just 5 -7 months" and " I STRONGLY Believe Gps will Reach the Primary Endpoint..." So Many Idiot short tools / retail traders too, getting FLEECED... $ABBV $A
View on StockTwits ↗$A Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma https://marketwirenews.com/stock/a/news/agilent-receives-eu-approval-for-pd-l1-ihc-22c3-phar-5150562317732921.html?utm_source=stocktwits
View on StockTwits ↗$A Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure https://marketwirenews.com/stock/a/news/gilead-to-present-new-hiv-research-at-aids-2026-acro-5182713870505921.html?utm_source=stocktwits
View on StockTwits ↗$A Lira Clinical Announces New REGEN Line - A First-of-Its-Kind Breakthrough in Regenerative Skincare https://marketwirenews.com/stock/a/news/lira-clinical-announces-new-regen-line-a-first-of-it-6694639445227332.html?utm_source=stocktwits
View on StockTwits ↗$A Quebec's Real Estate Market Gradually Rebalances in the Second Quarter https://marketwirenews.com/stock/a/news/quebec-s-real-estate-market-gradually-rebalances-in--6866626285772635.html?utm_source=stocktwits
View on StockTwits ↗$A Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma https://marketwirenews.com/stock/a/news/agilent-receives-fda-approval-for-pd-l1-ihc-28-8-pha-8339272714637069.html?utm_source=stocktwits
View on StockTwits ↗$A Jefferies has altered their rating of "Hold" and target of "$135" see consensus outlook
View on StockTwits ↗$GDC As of today (July 2026), there are exactly two public companies with Bitcoin treasuries reported at precisely 7,500 BTC:  • American Bitcoin Corp $A B TC — ~7,500 BTC (ranks around #16 on major trackers). • GD Culture Group ($GDC) — 7,500 BTC (ranks right behind or alongside ABTC). Key Context from Trackers Major sources like http://BitcoinTreasuries.net, CoinGecko, and others consistently list only these two at that exact round number. No other public companies (or prominent private/government entities) are currently reported with precisely 7,500 BTC.  Look at the difference in Market Caps 👇 🤷🏻♂️
View on StockTwits ↗$ADTX $A/ S 10B https://www.sec.gov/Archives/edgar/data/1641398/000121390025089638/ea0258126-pre14c_gdculture.htm
View on StockTwits ↗$A Share Price: $133.35 Contract Selected: Nov 20, 2026 $135 Calls Buy Zone: $10.58 – $13.07 Target Zone: $17.56 – $21.46 Potential Upside: 57% ROI Time to Expiration: 140 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$A Bernstein has altered their rating of "Outperform" and target of "$155" see consensus outlook
View on StockTwits ↗$SKM 🇰🇷 SK Telecom owns ~0.3% of Anthropic, bought early. L Here's what that 0.3% slice would be worth at different Anthropic valuations, and how big it looms next to SKT's own ~$14B market cap: $1.0T → $3.0B (~21% of SKT) $1.5T → $4.5B (~32%) $2.0T → $6.0B (~43%) $2.5T → $7.5B (~54%) So at a $2.5T Anthropic, the stake alone ≈ half of SKT's entire value. A pre-IPO backdoor into Anthropic. $A £maaft7h;
View on StockTwits ↗$A in the strong medtech space. Note the OBV indicator, how strong it is here with price still pretty muted. (just added this to the mix).
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.4B | +7.6% | $6.06 | $5.95–$6.11 | 22.9× | 12 |
| 2027 | $7.9B | +6.0% | $6.60 | $6.45–$6.68 | 21.0× | 13 |
| 2028 | $8.4B | +6.4% | $7.32 | $6.82–$7.93 | 18.9× | 6 |
| 2029 | $8.9B | +5.9% | $8.09 | $7.99–$8.25 | 17.2× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-27 | $1.41 | $1.49 | +5.7% |
| 2026-02-25 | $1.37 | $1.36 | -0.7% |
| 2025-11-24 | $1.58 | $1.59 | +0.4% |
| 2025-08-27 | $1.37 | $1.37 | +0.0% |
| 2025-05-28 | $1.26 | $1.31 | +4.0% |
| 2025-02-26 | $1.28 | $1.31 | +2.3% |
| 2024-11-25 | $1.41 | $1.46 | +3.5% |
| 2024-08-21 | $1.26 |
| $1.32 |
| +4.8% |
| $50.0B |
| — |
| HLNHaleon plc | $10.11 | -1.65% | $44.5B | — |
| INSMInsmed Incorporated | $101.49 | -1.58% | $22.0B | — |
Source: Financial Modeling Prep · peers by sector/industry